Kawai K, Kawai AT. Racial/ethnic and socioeconomic disparities in adult vaccination coverage. Am J Prev Med. 2021 Oct;61(4):465-73. doi: 10.1016/j.amepre.2021.03.023
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Forneris CA, Gartlehner G, Brownley KA, Gaynes BN, Sonis J, Coker-Schwimmer E, Jonas DE, Greenblatt A, Wilkins TM, Woodell CL, Lohr KN. Interventions to prevent post-traumatic stress disorder: a systematic review. Am J Prev Med. 2013 Jun;44(6):635-50. doi: 10.1016/j.amepre.2013.02.013
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prev Med. 2009 Nov 1;37(5):381-8.
Ellison RC, Rothman KJ, Zhang Y, Djousse L. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. Am J Prev Med. 2005 Oct 1;29(3):243.
Spencer DL, Reed (Earnshaw) SJ, Atkinson D, Kalsbeek WD. Design of a survey to inform state health decision making: a collaborative effort. Am J Prev Med. 1997 Nov 1;13(6 Suppl):69-74.